Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of Evista in Romania

TOKYO, Gurgaon, India, September 1, 2009 - Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) announced today that Terapia S.A. (“Terapia Ranbaxy”), a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication, Evista ® in Romania. This is the first time in Europe that Daiichi Sankyo and Ranbaxy are leveraging synergies generated through the Hybrid Business Model. Remarking on the development, Mr. Takashi Shoda, President & CEO of Daiichi Sankyo, said, “We are delighted to announce this latest of the many synergies we will realize through our cooperation with Ranbaxy. We continue to explore other collaborations with Ranbaxy that will help optimize our growth.”

Commenting on the occasion, Mr. Atul Sobti, CEO and Managing Director of Ranbaxy, said, “The launch of Evista by Terapia Ranbaxy in Romania marks our first international endeavour as a global partnership. Terapia Ranbaxy is a strong player in Europe, and we will provide a unique platform to Daiichi Sankyo for the launch of Evista, and many more new products in the future.”

With a population of 22 million people, Romania is Eastern Europe’s second biggest market after Poland. Annual turnover in the Romanian pharmaceutical market totals about $2.5 billion, and the market is growing at around 20 percent a year, in local currency terms. Established in 1921, Terapia, now Terapia Ranbaxy, has a strong brand name and a consistent track record of growth and profitability. It is the largest generic pharmaceutical company and is one of the seven largest pharmaceutical companies in Romania.

In 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six European countries from Eli Lilly and Company. In 2008, Daiichi Sankyo acquired additional rights for the drug covering all remaining countries in Europe, with the exception of Greece.

About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com

About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

For further information, please contact:
Daiichi Sankyo Co., Ltd.
3-5-1, Nihonbashi Honcho, Chuo-ku,Tokyo 103-8426, Japan  Toshiaki Sai
General Manager, Corporate Communications
Masaya Tamae
Director, Public Relations
Shigemichi Kondo
Director, Investor Relations Tel: +81-3-6225-1126
 

Pharma Industry News Archive

More News Resources

• Daily MedNews
• Pharma Industry News
• New Drug Applications
• New Drug Approvals
• Clinical Trial Results
• Generic Drug Approvals
• Monthly Update Archive